Phase I study of sunitinib with irinotecan/5-fluorouracil/leucovorin (FOLFIRI) for advanced gastroesophageal cancers

被引：0
|
作者：
Khushalani, N. I.
Fetterly, G. J.
Iyer, R. V.
Litwin, A.
Brady, W.
Javle, M. M.
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps201
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS201
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study of irinotecan/5-fluorouracil/leucovorin (FOLFIRI) with sunitinib for advanced gastroesophageal cancers (EGC).
    Mukherjee, Sarbajit
    Fountzilas, Christos
    Boland, Patrick McKay
    Attwood, Kristopher
    Tan, Wei
    Khushalani, Nikhil I.
    Iyer, Renuka V.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
    Sarbajit Mukherjee
    Christos Fountzilas
    Patrick M. Boland
    Rohit Gosain
    Kristopher Attwood
    Wei Tan
    Nikhil Khushalani
    Renuka Iyer
    Targeted Oncology, 2020, 15 : 85 - 92
  • [3] Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
    Mukherjee, Sarbajit
    Fountzilas, Christos
    Boland, Patrick M.
    Gosain, Rohit
    Attwood, Kristopher
    Tan, Wei
    Khushalani, Nikhil
    Iyer, Renuka
    TARGETED ONCOLOGY, 2020, 15 (01) : 85 - 92
  • [4] A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin
    Goldberg, RM
    Kaufmann, SH
    Atherton, P
    Sloan, JA
    Adjei, AA
    Pitot, HC
    Alberts, SR
    Rubin, J
    Miller, LL
    Erlichman, C
    ANNALS OF ONCOLOGY, 2002, 13 (10) : 1674 - 1680
  • [5] A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC)
    Fetterly, G. J.
    Brady, W. E.
    LeVea, C. M.
    Litwin, A. M.
    Zagst, P. D.
    Prey, J. D.
    Tarquini, M.
    Giardina, M. K.
    Iyer, R. V.
    Khushalani, N. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer
    Rogers, Jane E.
    Xiao, Lianchun
    Trail, Allison
    Blum Murphy, Mariela
    Palmer, Melissa
    Ajani, Jaffer A.
    ONCOLOGY, 2020, 98 (05) : 289 - 294
  • [7] Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers
    Allo, Gabriel
    Can, Ahu Damla
    Wahba, Roger
    Vogel, Nils
    Goeser, Tobias
    Kutting, Fabian
    Waldschmidt, Dirk
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (02)
  • [8] Phase I Study of Combination Therapy with Irinotecan, Leucovorin, and Bolus and Continuous-infusion 5-Fluorouracil (FOLFIRI) for Advanced Colorectal Cancer in Japanese Patients
    Sasaki, Yusuke
    Hamaguchi, Tetsuya
    Arai, Tatsuhiro
    Goto, Ayumu
    Ura, Takashi
    Muro, Kei
    Yamada, Yasuhide
    Shirao, Kuniaki
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2014, 34 (04) : 2029 - 2034
  • [9] A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan
    Midgley, R. S.
    Kerr, D. J.
    Flaherty, K. T.
    Stevenson, J. P.
    Pratap, S. E.
    Koch, K. M.
    Smith, D. A.
    Versola, M.
    Fleming, R. A.
    Ward, C.
    O'Dwyer, P. J.
    Middleton, M. R.
    ANNALS OF ONCOLOGY, 2007, 18 (12) : 2025 - 2029
  • [10] Phase I and Pharmacokinetic Study of Tegafur-Uracil/Leucovorin Combined With 5-Fluorouracil/Leucovorin and Irinotecan in Patients With Advanced Colorectal Cancer
    Chayahara, Naoko
    Tamura, Takao
    Yamamori, Motohiro
    Kadowaki, Yuko
    Okuno, Tatsuya
    Miki, Ikuya
    Tsuda, Masahiro
    Nishisaki, Hogara
    Maeda, Tetsuo
    Inoue, Yoshifumi
    Okumura, Katsuhiko
    Azuma, Takeshi
    Kasuga, Masato
    Sakaeda, Toshiyuki
    Hirai, Midori
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (01): : 56 - 60
12345